Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (canceled)

2. (previously presented) The pharmaceutical composition of claim 4, further comprising:

a carrier molecule that can be internalized by a living cell wherein the carrier molecule forms a conjugate with one or more Se(0) particles.

3. (canceled)

4. (previously presented) A pharmaceutical composition comprising:

elemental selenium (Se(0)) particles having a diameter of 0.4 to 5 nanometers; and

a pharmaceutically acceptable delivering medium.

5. (previously presented) A pharmaceutical composition comprising:

elemental selenium (Se(0)) particles having a diameter of 0.4 to 1 nanometer; and

a pharmaceutically acceptable delivering medium.

6. (previously presented) A pharmaceutical composition comprising:

elemental selenium (Se(0)) particles that can form a Se(0) colloid in a dispersion medium; and

a pharmaceutically acceptable delivering medium.

7. (original) The composition of claim 2, wherein the carrier molecule is target cell-specific.

8. (original) The composition of claim 2, wherein the carrier molecule is selected from the group consisting of proteins, glycoproteins and lipoproteins.

9. (original) The composition of claim 2, wherein the carrier molecule is selected from the group consisting of albumin, high density lipoprotein, low density lipoprotein and very low density lipoprotein.

10. (original) The composition of claim 2, wherein the carrier molecule is albumin.

11. (previously presented) The composition of claim 2, wherein the living cell is selected from the group consisting of a cancer cell, an immune cell responsible for an autoimmune disorder, an alloreactive lymphocyte responsible for graft-versus-host disease or a rejection reaction, a parasite and a parasitized blood cell.

12. (original) The composition of claim 2, wherein the living cell is a cancer cell.

13-25. (canceled)

26. (original) A method for generating Se(0) comprising the steps of:

providing a photosensitizing selone dye;

exposing the dye to light of a suitable wavelength in the presence of molecular oxygen; and

purifying Se(0).

27. (original) The method of claim 26, wherein the photosensitizing selone dye is selected from the group consisting of a selenomerocyanine dye and a selenooxonol dye.

28. (original) The method of claim 27, wherein the selenomerocyanine dye is selected from the group consisting of MC54, MC55, MC56 and MC57.

29. (original) The method of claim 26, wherein Se(0) is colloidal Se(0).

30. (original) The method of claim 26, wherein the light of suitable wavelength is generated by light-emitting diodes (LED).

31-51. (canceled)